MedTrace Logo

Cardiac Function and Biomarkers in Patients With Obesity and Overweight

NCT07455630 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2026-03-06

No results posted yet for this study

Summary

Obesity is a major public health problem worldwide and an established risk factor for cardiovascular disease. In individuals with obesity or overweight, systemic inflammation and endothelial dysfunction contribute to myocardial hypertrophy, ventricular remodeling, and alterations in cardiac morphology and function. Weight loss has been shown to improve metabolic and hemodynamic parameters; however, evidence regarding structural and functional cardiac reversibility remains limited.

This prospective single-center cohort study aims to evaluate changes in cardiac morphology and function (assessed by cardiac magnetic resonance imaging and echocardiography), as well as changes in inflammatory and cardiac biomarkers, in patients with obesity or overweight and cardiovascular risk factors who achieve at least a 10% reduction in body weight through pharmacological or non-pharmacological interventions.

Conditions

  • Obesity & Overweight

Interventions

DRUG

Weight loss with pharmacotherapy

Some participants may receive pharmacological treatment for weight loss as prescribed by their treating physician. All interventions are part of standard clinical care and are recorded for observational analysis.

BEHAVIORAL

Weight loss without pharmacotherapy

Participants receive individualized lifestyle counseling, including diet modification, physical activity recommendations, and behavioral strategies to achieve weight reduction. All interventions are part of standard clinical care and are documented for observational analysis.

Sponsors & Collaborators

  • TecSalud

    collaborator UNKNOWN

  • Fundación Santos y de la Garza Evia I.B.P

    collaborator UNKNOWN

  • TecSalud Investigación Clínica

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-20
Primary Completion
2023-09-19
Completion
2024-09-30

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07455630 on ClinicalTrials.gov